Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Xanthene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 3/20 | 0.94 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.94 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.50 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthene SCHEMBL11600668 | 1.00 | MAOA (0.94) | MAOAMAOBGAANPSR1NPC1 | |
| Xanthene SCHEMBL11602030 | 0.97 | MAOA (0.90) | MAOAMAOBGAANPSR1NPC1 | |
| Xanthene SCHEMBL27493963 | 0.97 | MAOA (1.00) | MAOAMAOBGAANPSR1NPC1 | |
| Xanthene SCHEMBL4267 | 0.97 | MAOA (1.00) | MAOAMAOBGAANPSR1NPC1 | |
| Xanthene SCHEMBL29378346 | 0.97 | MAOA (1.00) | MAOAMAOBGAANPSR1NPC1 | |
| Xanthene SCHEMBL9339684 | 0.97 | MAOA (1.00) | MAOAMAOBGAANPSR1NPC1 | |
| Xanthene SCHEMBL30586075 | 0.97 | MAOA (1.00) | MAOAMAOBGAANPSR1NPC1 | |
| Xanthene SCHEMBL23355281 | 0.94 | MAOA (0.94) | MAOAMAOBGAANPSR1NPC1 | |
| Xanthene SCHEMBL6192065 | 0.94 | MAOA (0.94) | MAOAMAOBGAANPSR1NPC1 | |
| Xanthene SCHEMBL11214757 | 0.94 | MAOA (0.94) | MAOAMAOBGAANPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327874-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2024-02-28 | — | — | EP | claimed |
| CN-102307878-A | 3, 6-disubstituted xanthylium salts | WISTA LAB LTD | 2012-01-04 | — | — | CN | claimed |
| EP-4327874-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2024-02-28 | — | — | EP | disclosed |
| EP-3689346-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS FOR TREATING TAUOPATHIES | WISTA LAB LTD (SG) | 2024-01-24 | — | — | EP | disclosed |
| EP-3689346-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2020-08-05 | — | — | EP | disclosed |
| EP-3112358-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LAB LTD (SG) | 2020-04-29 | — | — | EP | disclosed |
| US-10399955-B2 | 3,6-disubstituted xanthylium salts | WISTA LABORATORIES LTD. (SG) | 2019-09-03 | — | — | US | disclosed |
| US-20170088534-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LABORATORIES LTD. (SG) | 2017-03-30 | — | — | US | disclosed |
| US-9549933-B2 | 3,6-disubstituted xanthylium salts | WISTA LABORATORIES LTD. (SG) | 2017-01-24 | — | — | US | disclosed |
| EP-3112358-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2017-01-04 | — | — | EP | disclosed |
| EP-2373660-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | WISTA LAB LTD (SG) | 2016-08-17 | — | — | EP | disclosed |
| CN-102307878-B | 3, 6-disubstituted xanthylium salts | WISTA LABORATORIES LTD. (SG) | 2014-10-15 | — | — | CN | disclosed |
| US-20140161731-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LABORATORIES LTD. (SG) | 2014-06-12 | — | — | US | disclosed |
| US-8658665-B2 | 3,6-disubstituted xanthylium salts and use thereof in treatment of tauopathies | WISTA LABORATORIES LTD. (SG) | 2014-02-25 | — | — | US | disclosed |
| CN-102307878-A | 3, 6-disubstituted xanthylium salts | WISTA LAB LTD | 2012-01-04 | — | — | CN | disclosed |
| US-20110300074-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LABORATORIES LTD. (SG) | 2011-12-08 | — | — | US | disclosed |
| EP-2373660-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | Wista Laboratories Ltd. (SG) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010067078-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | WISTA LABORATORIES LTD. (SG) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161731-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | MAPT, PSEN2, PSEN1 | MAOA 1705/4885MAOB 1473/4885GAA 385/4885 |
| US-10399955-B2 | 3,6-disubstituted xanthylium salts | MAPT, PSEN2, PSEN1 | MAOA 1705/4885MAOB 1473/4885GAA 385/4885 |
| US-20170088534-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | MAPT, PSEN2, PSEN1 | MAOA 1705/4885MAOB 1473/4885GAA 385/4885 |
| US-20110300074-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | MAPT, PSEN2, PSEN1 | MAOA 184/4885MAOB 195/4885GAA 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.